Madrigal Pharmaceuticals, Inc. $MDGL Stock Position Raised by Peak Financial Advisors LLC

Peak Financial Advisors LLC grew its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 287.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,466 shares of the biopharmaceutical company’s stock after buying an additional 3,312 shares during the quarter. Madrigal Pharmaceuticals makes up about 1.2% of Peak Financial Advisors LLC’s investment portfolio, making the stock its 21st largest holding. Peak Financial Advisors LLC’s holdings in Madrigal Pharmaceuticals were worth $2,601,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in MDGL. Aventura Private Wealth LLC acquired a new position in Madrigal Pharmaceuticals in the fourth quarter worth approximately $36,000. Mather Group LLC. acquired a new stake in Madrigal Pharmaceuticals in the third quarter valued at approximately $33,000. Global Retirement Partners LLC lifted its stake in Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 51 shares during the last quarter. First Horizon Corp bought a new stake in Madrigal Pharmaceuticals in the third quarter worth approximately $34,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Madrigal Pharmaceuticals in the third quarter worth approximately $39,000. Institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MDGL shares. Zacks Research upgraded shares of Madrigal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Bank of America decreased their price objective on shares of Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating for the company in a report on Friday, February 20th. TD Cowen reissued a “buy” rating on shares of Madrigal Pharmaceuticals in a research report on Monday, January 12th. Piper Sandler raised their target price on Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an “overweight” rating in a report on Friday, December 19th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $571.00 price target on shares of Madrigal Pharmaceuticals in a research report on Wednesday, January 14th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $685.31.

Madrigal Pharmaceuticals Price Performance

NASDAQ MDGL opened at $461.93 on Thursday. The stock has a 50-day simple moving average of $463.40 and a 200 day simple moving average of $489.10. Madrigal Pharmaceuticals, Inc. has a twelve month low of $265.00 and a twelve month high of $615.00. The stock has a market capitalization of $10.60 billion, a PE ratio of -35.89 and a beta of -0.97. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.77 and a current ratio of 4.01.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($2.61). The business had revenue of $321.08 million during the quarter, compared to analyst estimates of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The business’s quarterly revenue was up 210.8% compared to the same quarter last year. During the same period last year, the business earned ($2.71) EPS. Research analysts anticipate that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Insider Buying and Selling

In related news, insider Carole Huntsman sold 419 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $180,982.86. Following the completion of the transaction, the insider directly owned 12,692 shares in the company, valued at $5,482,182.48. This represents a 3.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Rebecca Taub sold 491 shares of the stock in a transaction on Friday, March 6th. The shares were sold at an average price of $431.94, for a total transaction of $212,082.54. Following the completion of the sale, the director directly owned 452,213 shares of the company’s stock, valued at approximately $195,328,883.22. This trade represents a 0.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 55,612 shares of company stock valued at $28,326,065 in the last ninety days. Company insiders own 21.50% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.